What is ATHE stock price today?

ATHE (Alterity Therapeutics Ltd) stock is trading at $3.30 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is ATHE stock going up or down today?

ATHE stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy ATHE stock now?

The decision to buy ATHE depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is ATHE a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for ATHE based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is ATHE stock overvalued or undervalued?

Use our DCF valuation calculator to determine if ATHE is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is ATHE's P/E ratio?

P/E ratio data for ATHE will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is ATHE's market cap?

ATHE (Alterity Therapeutics Ltd) has a market capitalization of $0.06 billion, making it a small-cap stock.

What is ATHE's price to book ratio?

ATHE trades at a price-to-book (P/B) ratio of 2.20, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does ATHE pay dividends?

ATHE does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is ATHE's dividend yield?

ATHE does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is ATHE stock a good long-term investment?

ATHE's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is ATHE's revenue growth rate?

ATHE has shown revenue growth of 0.8% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

ATHE is currently operating at a loss. Some companies prioritize growth over profitability in early stages. Review our financial analysis for detailed insights.

What are the risks of investing in ATHE?

Key risks for ATHE include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does ATHE compare to its competitors?

Compare ATHE to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize ATHE's performance and positioning.

What is ATHE's stock price target for 2026?

Our AI model provides price targets for ATHE based on fundamental analysis: Bull case $4.29 (+30%), Base case $3.79 (+15%), Bear case $2.97 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about ATHE?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for ATHE. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is ATHE's next earnings report?

ATHE reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

ATHE - Alterity Therapeutics Ltd

NYSE * Healthcare * Biotechnology

$3.30

$-0.15 (-4.35%)

About Alterity Therapeutics Ltd

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as biomarkers of progression in multiple system atrophy. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.

ATHE Key Statistics

Market Cap

$59.81M

P/B Ratio

2.20

EPS

$-0.59

Revenue Growth

+0.8%

Profit Margin

-2.2%

Employees

How ATHE Compares to Peers

ATHE has the fastest revenue growth among competitors

ATHE is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

of 6

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
ATHE(This stock)	$59.81M	N/A	1%	-2.2%	-
AMGNAmgen Inc	$177.92B	25.6	0%	0.2%	vs AMGN
GILDGilead Sciences	$154.99B	19.3	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$113.16B	31.1	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$77.69B	17.6	0%	0.3%	vs REGN
BIIBBiogen Inc	$24.26B	15.1	0%	0.2%	vs BIIB

Alterity Therapeutics Ltd Company Information

Headquarters: 350 Collins Street, Melbourne, VIC, Australia, 3000, undefined
Website: alteritytherapeutics.com
Sector: Healthcare
Industry: Biotechnology

About Alterity Therapeutics Ltd

ATHE Key Statistics

How ATHE Compares to Peers

Alterity Therapeutics Ltd Company Information

Upcoming Events for ATHE